Subcutaneous amivantamab-lazertinib

The phase III PALOMA-3 study (NCT05388669) enrolled 418 patients with EGFR-altered advanced NSCLC who progressed after receiving osimertinib and platinum-based chemotherapy. Patients were randomly assigned in a 1:1 ratio to receive either subcutaneous or IV amivantamab. Patients in both groups also received lazertinib.[31]

The phase III PALOMA-3 study (NCT05388669) enrolled 418 patients with EGFR-altered advanced NSCLC who progressed after receiving osimertinib and platinum-based chemotherapy. Patients were randomly assigned in a 1:1 ratio to receive either subcutaneous or IV amivantamab. Patients in both groups also received lazertinib.[31]

The objective response rate was 30% (95% CI, 24%–37%) in the subcutaneous amivantamab group and 33% (95% CI, 26%–39%) in the IV amivantamab group. The median PFS was 6.1 months (95% CI, 4.3–8.1) in the subcutaneous amivantamab group and 4.3 months (95% CI, 4.1–5.7) in the IV amivantamab group.[31][Level of evidence A1]

The phase III PALOMA-3 study (NCT05388669) enrolled 418 patients with EGFR-altered advanced NSCLC who progressed after receiving osimertinib and platinum-based chemotherapy. Patients were randomly assigned in a 1:1 ratio to receive either subcutaneous or IV amivantamab. Patients in both groups also received lazertinib.[31]

The OS was significantly longer in the subcutaneous amivantamab group than the IV amivantamab group (HRdeath, 0.62; 95% CI, 0.42–0.92; nominal P = .02).

The phase III PALOMA-3 study (NCT05388669) enrolled 418 patients with EGFR-altered advanced NSCLC who progressed after receiving osimertinib and platinum-based chemotherapy. Patients were randomly assigned in a 1:1 ratio to receive either subcutaneous or IV amivantamab. Patients in both groups also received lazertinib.[31]

Infusion-related reactions occurred in 13% of patients in the subcutaneous amivantamab group and 66% of patients in the IV amivantamab group. Venous thromboembolism occurred in 9% of patients in the subcutaneous amivantamab group and 14% of patients in the IV amivantamab group.

The phase III PALOMA-3 study (NCT05388669) enrolled 418 patients with EGFR-altered advanced NSCLC who progressed after receiving osimertinib and platinum-based chemotherapy. Patients were randomly assigned in a 1:1 ratio to receive either subcutaneous or IV amivantamab. Patients in both groups also received lazertinib.[31]

The median administration time for the first infusion was 4.8 minutes (range, 0–18) in patients who received subcutaneous amivantamab and 5 hours (range, 0.2–9.9) in patients who received IV amivantamab.